Regulatory Roundup, Week of November 19, 2012 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Regulatory Roundup, Week of November 19, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

The United States Pharmacopeial Convention (USP) has announced a new drug naming policy to take affect May 1, 2013. USP worked on the new policy with FDA and industry stakeholders to clarify naming practices for medicines and make them more consistent. According to USP, “the policy will apply prospectively to drug product and compounded preparation monographs that appear in USP’s compendia of public quality standards—the United States Pharmacopeia and National Formulary (USP–NF).”  For more information, visit USP’s website at

USP has also announced its “Fifth Bioassay Workshop,” which will be held on Dec. 4-5, 2012 at USP headquarters in Rockville, MD. The workshop will focus on the development, monitoring, and validation of bioassays. Visit USP's website for more information.

FDA has made available, Guidance on Q11 Development and Manufacture of Drug Substances. FDA intends the guidance to “harmonize the scientific and technical principals relating to the description and justification of the development and manufacturing process of drug substances….”  

Also released by FDA on November 19, 2012 is Guidance for Industry, Electronic Source Data in Clinical Investigations.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here